Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Interventional Medicine & Applied Science|October 27, 2018
Determination of the psychometric properties of the Patients' Self-Efficacy Scale in blood pressure patientsRaheleh Ghadiri, Masoumeh Alimohammadi, Hesamedin Askari Majdabadi
Environmental Monitoring and Assessment|February 13, 2014
Assessment of soil screening levels due to ingestion and dermal absorption of chrysene and benzo[k]fluoranthene and appropriate remediation method for Dorson AbadSaeid Gitipour, Saeid Firouzbakht, Ehsan Mirzaee, et al.
Avicenna Journal of Medical Biotechnology|December 11, 2023
Radiotherapy Combination: Insight from Tumor Immune Microenvironment (TIME)Masoumeh Alimohammadi, Haniyeh Ghaffari-Nazari, Reza Alimohammadi, et al.
Reviews in Medical Virology|May 2, 2022
Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studiesMona Sadeghalvad, Amir Hossein Mansourabadi, Maryam Noori, et al.
Scientific Reports|February 11, 2023
Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor modelReza Alimohammadi, Ghanbar Mahmoodi Chalbatani, Masoumeh Alimohammadi, et al.
International Immunopharmacology|April 13, 2022
Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor modelHaniyeh Ghaffari-Nazari, Masoumeh Alimohammadi, Reza Alimohammadi, et al.
Current Research in Translational Medicine|December 21, 2025
Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical blood cord NK cells for targeting CD19⁺ primary B-ALL cellsHossein Salehi-Shadkami, Mosslim Sedghi, Shima Tavoosi, et al.
Plos One|August 26, 2022
Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironmentsElham Rostami, Mohsen Bakhshandeh, Haniyeh Ghaffari-Nazari, et al.
International Immunopharmacology|May 18, 2024
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-upMohammadreza Salehi, Ilad Alavi Darazam, Alireza Nematollahi, et al.
NPJ Vaccines|September 2, 2022
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primatesReza Alimohammadi, Meysam Porgoo, Mohamad Eftekhary, et al.
Pageof 1